Publication: Advances in the development of AMPK-activating compounds
Issued Date
2008-10-01
Resource Type
ISSN
17460441
Other identifier(s)
2-s2.0-55049121166
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Expert Opinion on Drug Discovery. Vol.3, No.10 (2008), 1167-1176
Suggested Citation
Apiradee Sriwijitkamol, Nicolas Musi Advances in the development of AMPK-activating compounds. Expert Opinion on Drug Discovery. Vol.3, No.10 (2008), 1167-1176. doi:10.1517/17460441.3.10.1167 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/19864
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Advances in the development of AMPK-activating compounds
Author(s)
Abstract
Background: AMP-activated protein kinase (AMPK) is an energy sensing enzyme that controls glucose and lipid metabolism. Objective: This review summarizes the present data on AMPK as a pharmacologic target for the treatment of metabolic disorders. Methods: The mechanisms governing AMPK activity and how this enzyme controls different metabolic pathways are reviewed briefly, and details about the effect that AMPK activators have on glucose metabolism are provided. Conclusion: Evidence obtained using the AMPK-activating compound 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) suggests that AMPK promotes glucose transport into skeletal muscles and that this enzyme inhibits hepatic glucose production. AICAR also induces fatty acid oxidation in muscle and inhibits cholesterol synthesis in the liver. The metabolic effects of AICAR on glucose and lipid metabolism indicate that AMPK may be a good pharmacologic target for the treatment of type 2 diabetes and hypercholesterolemia. Novel AMPK-specific compounds are allowing researchers to examine whether this enzyme is a useful pharmacologic target for the treatment of human disease and whether chronic activation of AMPK will be safe. © 2008 Informa UK Ltd.
